Blog

Nov 6, 2026

Weight regain after stopping a GLP-1 receptor agonist is the rule rather than the exception. A 2026 systematic review and meta-regression of six randomised trials found that about 60% of the weight lost on treatment returns within a year of stopping, following a predictable curve that then slows. Only one approach has been tested against […]

Oct 31, 2026

In the SURMOUNT-1 trial, tirzepatide produced mean weight reductions of 15.0%, 19.5% and 20.9% at 5 mg, 10 mg and 15 mg respectively by week 72, compared with 3.1% on placebo. Most of that loss accumulated across the first six to nine months, and a post-hoc analysis found the median time to weight plateau was […]

Oct 22, 2026

No food is pharmacologically forbidden on Ozempic. There is no food-drug interaction with semaglutide of the kind that exists for some other medications. What does exist is a predictable list of foods that worsen the gastrointestinal effects the medication already produces — chiefly high-fat and fried foods, very large portions, alcohol, and carbonated drinks. Avoiding […]

Oct 11, 2026

Retatrutide reported larger average weight loss than tirzepatide in phase 3 trials, but it is not an available treatment. In TRIUMPH-1, retatrutide 12mg was reported to produce 28.3% mean weight reduction at 80 weeks; tirzepatide produced 20.2% at 72 weeks in the peer-reviewed head-to-head SURMOUNT-5 trial. Tirzepatide is FDA-approved and prescribable today. Retatrutide is investigational: […]

Oct 2, 2026

Ozempic and Wegovy are not injected the same way, and the operational steps for each come from the Instructions for Use (IFU) in your medication carton — not from any article. Ozempic uses a multi-dose pen that requires a new needle each time, a flow check before the first use of each pen, dose selection, […]

Sep 23, 2026

GLP-1 medications are a class of injectable and oral drugs that mimic glucagon-like peptide-1, an incretin hormone the gut releases after eating, to lower blood glucose and reduce appetite. The class has been in clinical use since 2005 and now spans seven molecules across roughly a dozen brand names, approved for type 2 diabetes, chronic […]

Sep 15, 2026

Ozempic (semaglutide) is not recommended during pregnancy, and the FDA-approved prescribing information advises discontinuing it at least 2 months before a planned pregnancy. The washout period reflects semaglutide’s elimination half-life of approximately one week, which means roughly five weeks are required for 97% clearance, plus a deliberate safety margin. Animal reproduction studies showed embryo-fetal harm […]

Sep 8, 2026

Ozempic (semaglutide) has a US list price of approximately $968 to $1,029 per month as of April 2026, but most uninsured patients do not pay this amount. Through NovoCare Pharmacy and GoodRx’s Novo-backed program, Ozempic is available to eligible cash-pay patients at $349 per month for 0.25mg, 0.5mg, and 1mg doses, or $499 per month […]

Aug 26, 2026

Ozempic (semaglutide 0.5mg, 1mg, 2mg) is FDA-approved for type 2 diabetes and produces gastrointestinal side effects in the majority of patients — primarily nausea, diarrhea, vomiting, and constipation — most prominently during dose escalation. These effects are dose-dependent and class-wide across all GLP-1 receptor agonists. In the SUSTAIN-1 trial, nausea occurred in approximately 15 to […]

Aug 18, 2026

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both weekly injectable GLP-1 receptor agonists used for weight management and metabolic disease, but they work through different mechanisms and produce substantially different outcomes. Tirzepatide adds GIP receptor agonism to GLP-1 receptor activation, producing greater average weight loss (approximately 20% vs. 15% in head-to-head SURMOUNT-5 data), stronger glucose lowering, […]

Aug 10, 2026

Wegovy and Ozempic contain the same active ingredient — semaglutide — but they are different products with different FDA approvals, different doses, and critically different insurance coverage implications. Wegovy (semaglutide 2.4mg) is FDA-approved for chronic weight management. Ozempic (semaglutide 0.5mg, 1mg, 2mg) is FDA-approved for type 2 diabetes. Using one when you need the other […]

Aug 1, 2026

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes — not for weight loss. However, off-label prescribing for weight management is common in clinical practice, and the molecule’s weight loss data from the SURMOUNT trials (up to 20.2% body weight reduction) is among the strongest in obesity pharmacology. Zepbound is the same tirzepatide molecule with an […]